Chinese drug authority accepts Eisai\'s NDA for Perampanel to treat partial onset seizures

Chinese drug authority accepts Eisai's NDA for Perampanel to treat partial onset seizures

Eisai Co, Ltd has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai's antiepileptic drug (AED) perampanel (generic name, product

More From BioPortfolio on "Chinese drug authority accepts Eisai's NDA for Perampanel to treat partial onset seizures"